Previous preclinical safety studies in ewes have found intravenous levobupivacaine and ropivacaine to be less potent toward causing central nervous system (CNS) and cardiac toxicity than bupivacaine. Analogous cardiotoxicity has been demonstrated directly in various cardiac preparations ex vivo. Moreover, drug-related arrhythmogenicity has been demonstrated from direct CNS injection of local anesthetic agents in vivo, suggesting CNS-related cardiotoxicity. This study investigated whether CNS site-directed blood-borne drug administration (with minimal systemic recirculation) would demonstrate drug-related cardiotoxicity.


Direct CNS effects and indirect cardiotoxic sequelae were determined after bilateral carotid arterial infusions of levobupivacaine, bupivacaine, or ropivacaine in ewes. After pilot studies to validate the procedures, equimolar doses (24-96 micromol, approximately 7.5-30 mg) were infused over 3 min using a crossover design. Behavioral CNS signs, quantitative electroencephalographic (EEG), cardiovascular, and electrocardiographic effects were recorded. Drug blood concentrations in superior sagittal sinus and aorta were measured serially.


Blood drug concentrations in the superior sagittal sinus were 5-10 times those concurrently in the aorta, confirming highly selective CNS delivery with minimal systemic recirculation. Dose-dependent CNS excitatory behavior and EEG changes, with increased mean arterial blood pressure, heart rate, cardiac output, and myocardial contractility, were found, consistent with sympathetic nervous system stimulation. The overall rank order of potency for these effects was ropivacaine < levobupivacaine < bupivacaine. Nonfatal cardiac arrhythmias were observed, but the type or frequency did not differ between drugs.


Although CNS site-selective drug delivery produced quantitative differences between bupivacaine, levobupivacaine, and ropivacaine in some CNS effects and cardiac sequelae, no differences were found in their arrhythmogenic potential.

PREVIOUS preclinical studies to evaluate safety have found the enantiopure long-acting local anesthetic agents levobupivacaine (S -bupivacaine) and ropivacaine to be less potent in causing central nervous system (CNS) and cardiac toxicity than (racemic) bupivacaine when administered intravenously to conscious adult female sheep. 1–6Such findings concur with various other laboratory experiments that have found dexbupivacaine (the R -bupivacaine enantiomer component of bupivacaine) more toxic to the CNS and heart than levobupivacaine. 7–12 

Local anesthetic-induced cardiac toxicity affects myocardial contractility (quantitated by decreased left ventricular dP/dtmax) and electrical activity (quantitated by QRS complex widening and arrhythmia frequency). 13Whereas the potency of the local anesthetic agents in depressing myocardial contractility is essentially proportional to their local anesthetic potency, that for disrupting electrical activity is disproportionately greater for bupivacaine than for levobupivacaine or ropivacaine. However, concurrent CNS toxicity complicates the presentation of cardiac toxicity because CNS excitatory behavior opposes the myocardial depressant activity and may itself generate cardiac conduction abnormalities. 13Local anesthetic agents injected directly into the CNS at or near brain stem 0regions of cardiac control can generate cardiac arrhythmias. 14,15Moreover, the effects of intravenous bupivacaine in decreasing the firing rate of relevant brain stem cells are enantioselective. 16Thus, local anesthetics apparently can cause indirect cardiotoxicity by their direct actions on the brain and brain stem, with enantioselectivity as found with intravenous administration.

This study was conceived to gain insight into the role of CNS effects in cardiac toxicity from local anesthetic agents while the cardiovascular system was exposed to only subtoxic amounts of drug. It involved the CNS site-directed carotid arterial infusion of the drug and determined the direct CNS toxicity and the indirect cardiac sequelae, focusing on arrhythmogenesis. It was designed to complement a previous study of cardiac site-directed coronary arterial infusions of the same drugs in which the CNS was exposed to only subtoxic amounts of drug. 17 


The studies were approved by the local animal care and ethics committee. The subjects were nonpregnant Merino cross-bred ewes, aged approximately 18–24 months, and weighing between 44 and 57 kg (table 1).


Surgical preparation was performed in two stages with the animal given general anesthesia. A left thoracotomy was performed for the placement of probes for hemodynamic and electrocardiographic (ECG) measurements. A second surgery was performed 7–10 days later for placement of infusion and sampling cannulae in the carotid arteries and superior sagittal sinus, a transit-time blood flow probe on the superior sagittal sinus, and electroencephalographic (EEG) electrodes.

During general anesthesia, a left thoracotomy was performed via  the left 4/5 intercostal space. A flow probe (21 mm ART2, Triton Technology Inc, San Diego, CA) was implanted around the pulmonary artery for cardiac output monitoring. A pressure transducer catheter (3.5-French Millar SPR-524, Millar Instruments Inc., Houston, TX) was placed into the left ventricle through the left ventricular free wall. The pericardium was closed, and two pairs of stainless steel internal ECG electrodes were sutured onto pericardium. All leads were exteriorized by tunneling subcutaneously to near midline of the dorsum. Bupivacaine intercostal nerve block was implemented just before thoracic closure. In addition, postoperative pain was managed by intravenous carprofen, 75 mg, and buprenorphine, 0.3 mg, injections after completion of surgery, followed by buprenorphine two or three times daily for 4 or 5 days at the discretion of the clinical investigators.

In the second surgery also performed with general anesthesia, each carotid artery was dissected free from surrounding tissue, and a polyurethane cannula (18 gauge, 70 cm, Cavafix, B Braun Melsengen AG, Melsengen, DE) was placed each side, to a depth of about 10 cm caudally, for the measurement of blood pressure and for arterial blood sampling; an epidural catheter (22 gauge, Spinocath, B Braun Melsengen AG, Melsengen, DE) was placed into each carotid artery 5 cm cranial to the sampling catheter to a depth of 3 or 4 cm for drug infusion in a retrograde manner. All catheters were introduced through half wall thickness purse-string sutures to guard against arterial leakage and were tunneled and exteriorized dorsally from the back of the neck. After midline trephination of the skull over bregma, a cannula (22 gauge, Spinocath, B Braun, Melsengen AG, Melsengen, DE) was placed in the superior sagittal sinus for sampling blood. Stainless steel EEG electrodes were introduced bilaterally through the trephination to reside between the skull and cerebral cortex. A transit-time flow probe (4ss, Transonic System Inc, Ithaca, NY) was placed on the sagittal sinus for measurement of blood flow. 18All cannulae, except for the two carotid arterial infusion lines, were then attached to a constant infusion of heparinized saline, 3 ml/h, via  minimum volume extension sets connected to high-pressure, low-flow restrictor devices. These were attached via  a multiple port block from a pressurized 1-l saline bag, 0.9%, with heparin, 10,000 U, and flucloxacillin, 1 g, added and kept pressurized by a cylinder of medical oxygen regulated to 300 mmHg. The carotid infusion lines were flushed at least three times a week with 50% glucose (heparinized, 240 U/ml). After the second surgery, the animals were allowed to recover in a metabolic crate for a minimum of 1 week before the first study was performed. Postoperative pain was managed as described previously. The animals were also given a clinical examination twice daily for several days after both surgical procedures.

Drugs and Doses

Equimolar doses of levobupivacaine HCl (Chirocaine, Chiroscience R&D Ltd, Cambridge, UK), bupivacaine HCl (Marcaine, Delta West, Perth, Australia), and ropivacaine HCl (Naropin, AstraZeneca Pty Ltd, Sydney, Australia) in 15 ml 0.9% saline were infused over 3 min. The relevant researchers were blinded to the drug identities, and the code was broken after completion of the data analysis.

Experimental Details

Because of the paucity of previously published information about the perfusion of the cortical and medullary areas of the sheep brain via  the basilar and carotid arteries, preliminary studies of the cerebral vascular anatomy were performed using dissection and brachiocephalic arterial erosion cast techniques in dead animals. Our approach was based on various studies showing that carotid arteries supply all above brain stem in sheep 19–21and was validated by vascular anatomy erosion casts and by pilot studies.

Pilot studies were performed with bupivacaine in seven animals during general anesthesia to validate the drug infusion procedures, signal processing, dose ranging, and to gauge the effect on drug regional brain distribution from ligation of the vertebral arteries. The latter point arose from rationalization that the veil of pressure within the circle of Willis might be manipulated to deliver drug preferentially to cortex or brain stem. However, the pilot data did not provide evidence to support the theory that ligation of vertebral arteries would cause redistribution of blood to the brain stem so that the simpler preparation (without interference to the vertebral arteries) was used for the systematic studies. After evaluation of the pilot studies (see Results section), it was decided to use a crossover design so that each animal received the drugs in random order, in blocks of increasing dose. One threshold convulsant dose (24 μmol ≈7.5 mg) and up to three supraconvulsant doses (48, 72, and 96 μmol) were used as described in table 1.

On the day of each study, the subject animal was brought into the laboratory with a companion animal, placed in a sling, and allowed to settle. Each study session consisted of three uninterrupted periods: 5 min, for baseline measurements; 30 min, beginning with a 3-min infusion of 15 ml 0.9% saline as a control; 30 min, beginning with a 3-min infusion of drug. The infusions were administered equally bilaterally via  the intracarotid arterial infusion cannulae by a Harvard model 22 programmable syringe pump operating in constant rate delivery mode.

Measurements included ECG arrhythmia analyses, QRS width, PR interval, QT interval, RR interval from which heart rate was derived, cardiac output, stroke volume derived from the ratio of cardiac output to heart rate, mean arterial blood pressure, left ventricular pressure, and the maximum positive value of its differential (dP/dtmax) as an index of myocardial contractility. In addition, the quantitative EEG signal was recorded continuously, and the semiquantitative Central Effects Index (CEI) of behavioral effects was derived from a videotape record of the study. 22Briefly, the CEI consisted of the same investigator assigning the times of onset and, if clearly obvious, the offset along with serial scores on a scale of 0 (no apparent effect) to 100 (death) of sets of discrete behaviors ranked in severity and modeled according to a logistic population growth equation using the onset of convulsive behavior (CEI = 70) and death as point attractors. Its maximum value and area under the time–effect curve (respectively, peak CEI and AUC CEI) thus provide measures of intensity and duration of CNS behavioral effect for each dose of drug. 23The 5-min periods immediately preceding the saline and drug infusion periods were considered the relevant respective baseline periods for assessment of the effects of the saline control and drugs.

Verification of the selective site drug delivery was made through drug analysis of arterial and sagittal sinus serial blood samples, 23from which the maximum measured blood drug concentration (Cmax) was noted. At the conclusion of the set of experiments, animals were anesthetized with pentobarbital, and food dye was immediately injected into the carotid artery cannulae followed 30 s later by an intracardiac injection of KCl. Tissue dye distribution and the probe placements were examined at post mortem. Subjects were to have been rejected if the dye distribution had failed to target the brain tissues as predicted.

Data Acquisition and Processing

Data from the various physiologic signals were gathered and stored digitally on a personal computer using AcqKnowledge 3.03 software (Biopac Systems Inc, Santa Barbara, CA) for postrun processing in a manner consistent with our previous and related study of site-directed coronary arterial infusion of the same drugs. 17 

Cardiovascular and hemodynamic data were broken into 20-s epochs, and the means of values from each epoch were calculated and charted as continuous plots. ECG data were broken into 1-min baseline epochs; after the commencement of drug infusion, the data were broken into 30-s epochs to 8 min, 1-min epochs to 10 min, 2-min epochs to 20 min, 5-min epochs to 30 min, and 15-min epochs to 60 min. ECG measurements were determined as averages from five consecutive complexes toward the end of the epoch. QTc duration was derived from QT and RR according to the formula QTc = QT/√(RR). Arrhythmias were analyzed by recording the numbers of abnormal beats for each type of arrhythmia present 17to give the proportions of abnormal to the total number of beats within the time window; the same investigator analyzed all ECGs to maintain consistency of interpretation.

Quantitative EEG signals were analyzed for the 24- and 48-μmol doses in four frequency bands, 1–4 Hz, 4–8 Hz, 8–13 Hz, and 13–30 Hz, by Bartlett and Blackman window digital filtering. Data in the windows were rectified along with an unfiltered waveform, and the absolute voltages were averaged over 20-s epochs and plotted over time.

Data and Statistical Analyses

Data consisting of the differences between values in the saline control or drug periods and their respective baseline periods were, for convenience of comparison, expressed as percentages of the individual baseline values determined in the specific animal during the specific session. Data were analyzed for the magnitude and time of peak effects (Emax). In addition, the sum of the effect differences to 10 min (SED10) for cardiovascular and hemodynamic data and to 5 min (SED5) for ECG data were determined to capture differences between treatments (drugs and doses) in the magnitude and immediate time course. SED data are often used in studies of analgesic drug effects; they provide a useful univariate statistic for time series data and are analogous to AUC. 24 

Drug effect data were analyzed by fitting random effects linear models 25using the cross-sectional time series regression facility (XTREG) of the statistical software Stata version 6 (Stata Corporation, College Station, TX). The random effects models allowed the fitting of dose–effect curves for all drug doses simultaneously while making allowance for random variation in level of effect among animals. Dose–effect relationships were tested for linearity by adding a quadratic term in dose and for parallelism by adding terms describing interactions between the linear dose trend and drug. Baseline values were included in the initial models as an explanatory covariate. 26If a significant difference among dose–effect curves of the three drugs was found, curves of the drugs were compared pair-wise using Wald tests. The null hypothesis was that there was no difference in effects between the three drugs. A significance criterion of P < 0.05 was taken as weak evidence for rejection of the null hypothesis; a significance criterion of P < 0.01 was taken as strong evidence. All tests were two tailed.

Cranial aortic erosion casts enabled the three-dimensional vascular anatomy to be visualized, and this assisted in placement of catheters (fig. 1). Because of the complexity and small size of most relevant afferent blood vessels, the carotid arterial infusion catheters could not be advanced to deliver blood-borne drug only to the brain; other craniofacial structures were also supplied concurrently. Hence, a conservative approach was adopted to place the catheter tip at a predefined point and thus to direct the drug dosage to the brain. The pilot studies verified the site-directed drug delivery approach by showing that brain tissue drug concentrations were similar to those found with fatal intravenous infusions of much larger doses. 1,27The pilot studies also found that the brain stem regional average drug concentrations were approximately 50–70% of the higher CNS regions (fig. 2). A drug crossover, dose block paradigm thus was chosen to minimize the impact of individual anatomic variations; data from 11 animals were used in the final analysis (table 1;figs. 3–9).

Relevant Pharmacokinetics

As predicted from the vascular erosion casts and pilot experiments, drug blood concentrations in the superior sagittal sinus were approximately 5–10 times those concurrently in the aorta, indicating a highly selective site direction to the brain with minimal recirculation of drug in the arterial blood (fig. 3). Cmaxwas essentially linear with dose, and there were no systematic differences between drugs (fig. 4).

Systemic Drug Effects

No significant effects resulted from the infusion of saline as a control agent. With infusion of local anesthetic drugs, two animals died at 3.5 and 5.8 min as a sequel to severe hypoxemia and respiratory acidosis after infusion of 96 μmol of bupivacaine. In one of these sheep, respiratory arrest contributed to the development of hypoxia and acidosis. The deaths were not caused by an arrhythmia, but after effective cardiac output had ceased and before (terminal) electrical asystole, some electrical abnormalities were seen in both sheep, including ventricular asystole with complete AV block. Significant differences in drug effects were found in Emaxand SED data of the chosen measures (table 2, figs. 5–9) but not in the time at which Emaxoccurred (data not shown). Dose–effect relationships, generated by the statistical analysis procedures, were parallel for the three drugs with the exception of PR interval, in which case the drug effects were compared at each dose. Differences between drugs are shown in table 2as the 95% confidence intervals of the magnitude of the effect difference in the dose–effect curves for respective pairs of drugs; a summary of rank order of overall effect potency is also shown. It is reiterated that comparisons were made using drug-induced changes from baseline determined in each animal during the relevant experimental session. In this way, individual differences in sensitivity between animals, either inherent or by preparation, were accommodated by the random effects data analysis models.

Central Nervous System Effects

Central Effects Index.

All doses of all drugs produced dose-related CNS excitatory effects in all animals. The 24-μmol doses produced hypertonia and sometimes convulsions. Convulsions occurred regularly with all larger doses, along with a maximal peak CEI. There were significant differences between drugs in peak CEI at the 24-μmol dose only, where ropivacaine was less than with bupivacaine (P = 0.007) and levobupivacaine (P = 0.001). AUC CEI was greatest with bupivacaine and least with ropivacaine (ropivacaine < bupivacaine [P < 0.001] and levobupivacaine [P = 0.016]; levobupivacaine < bupivacaine [P = 0.033]); the increase in AUC CEI with dose was essentially the result of increased duration of effect as peak effects were maximal (fig. 5).

Quantitative Electroencephalograms.

There was little change from baseline EEG with 24-μmol doses, but significantly increased power was clear from 48 μmol (fig. 6). Considering the Emaxvalues (as % baseline), there were differences in amplitude between drugs in the whole 1- to 30-Hz spectrum and in the 1- to 4-Hz band, where bupivacaine was greater than ropivacaine (respectively, P = 0.003 and P = 0.014), but not in the other separate frequency bands. There were significant differences between drugs across doses when considering SED10for the entire 1- to 30-Hz spectrum (bupivacaine > ropivacaine [P < 0.001] and levobupivacaine > ropivacaine [P = 0.038]) and for the separate 1- to 4-Hz band (bupivacaine > ropivacaine [P = 0.001]). A periodic epileptiform pattern, consisting of discharges followed by quiescence that resembled burst suppression, precluded quantitative EEG analysis for 72- and 96-μmol doses. Overall, the duration of effect was greatest with bupivacaine and least with ropivacaine.

Cardiovascular and Hemodynamic Effects

Dose-dependent increases in mean arterial blood pressure, heart rate, cardiac output, and left ventricular dP/dtmax, along with a decrease in stroke volume, were found. The time course of effects on heart rate after drug administration is shown in figure 7as being representative of time course of the effects. Dose–effect relationships are shown in figure 8. The overall rank order of potency for these effects across all doses was bupivacaine was greater than levobupivacaine, which was greater than ropivacaine, except for effects on stroke volume where there was no overall significant difference between drugs at doses greater than 24 μmol (table 2). Mean stroke volume, however, decreased with all three drugs: at 24-μmol dose (only), the effects of bupivacaine were the greatest, and those of ropivacaine were the least.

Electrocardiographic Effects

Mean PR interval, QRS width, and mean QTc interval decreased for the three largest doses of all three drugs, following the time course of changes in heart rate (fig. 9). Cardiac arrhythmias, predominantly premature ventricular and supraventricular ectopic beats, some in bigeminy or trigeminy, and ventricular tachycardias, some of which were multiform, were observed from some doses of all of the local anesthetic agents. Their frequencies, corrected for the prevailing heart rate as stimulated by the doses of the drugs, averaged between 1–3 aberrant beats per 100, without differences between drugs. At the 24-μmol dose, premature ectopic beats were noted without significant ventricular tachycardia. At doses of 48 μmol or greater, a preponderance of ventricular tachycardia was noted with all three drugs and which tended to decrease with increased dose.

This study demonstrated the feasibility of site-directed administration of blood-borne local anesthetic agents to the brain for determination of their direct CNS effects and indirect cardiac effects in chronic intact conscious animals. It found that local anesthetic drugs infused bilaterally into the carotid arteries of conscious sheep caused dose-related direct CNS and indirect cardiac effects with an overall rank order of potency bupivacaine > levobupivacaine > ropivacaine. Fatal arrhythmias were not found, and there were no differences between the drugs in producing nonfatal arrhythmias.

In the design of the studies, it was considered necessary to avoid general anesthesia and acute surgical stress. General anesthesia can alter the toxic response to local anesthetic agents 28,29and the disposition of drugs. 30These complications were precluded by using a conscious, previously instrumented, preparation. To ensure the appropriate distribution of the drug as would occur in the accidental intoxication of a clinical patient, it had to be administered to the brain as a blood-borne solute—but without delivering potentially toxic drug blood concentrations to the heart. After preliminary investigation of the cerebrovascular anatomy in relation to the routes of regional drug delivery to brain, a discrete dose paradigm was designed with bilateral carotid arterial infusion (using small cannulae to not compromise the normal carotid blood flow). As judged by regional CNS tissue bupivacaine concentrations in pilot studies (fig. 2), drug delivery to the brain stem was abundant but was relatively less than to higher structures. Enantiomeric differences in CNS tissue uptake of bupivacaine, however, were not apparent.

In the systematic studies, it was found that drug blood concentrations in the superior sagittal sinus exceeded those concurrently in the aorta by a factor of approximately 5 (figs. 3 and 4). This verified that drug delivery to the CNS was much enriched compared with the rest of the body, whereas the magnitude of the aortic concentrations verified pharmacologically trivial drug delivery to the heart. Equivalent brain drug concentrations from intravenous infusions necessitate much larger doses to be applied to the whole body so that direct cardiovascular effects would also occur. 1,27 

The potential for relatively small doses of local anesthetic agents to cause CNS toxicity if directed to the brain is widely recognized clinically but is poorly documented pharmacologically. After clinical observation of unexpected CNS effects from local anesthetic agents injected around the head or neck, it was suggested that retrograde transport via  arterial blood to the CNS may have been involved. 31,32Local anesthetic drugs have complex CNS effects. Tetraphasic EEG effects have been described in cats; the actions were found to be dose-dependent and progressed from depression to epileptiform stimulation with increasing rates of infusion, 33suggesting effects at a common receptor(s), probably a neuronal Na+channel. In our study, the overall severity of CNS effects increased in the same rank order of potency as found by others with intravenous administration in a variety of preparations, i.e. , ropivacaine < levobupivacaine < bupivacaine. 13In this study, intracarotid doses of 48 μmol or greater (≈15 mg) almost always caused frank convulsive behavior. Overt CNS effects were always accompanied by cardiovascular changes, consistent with an abrupt onset of sympathetic nervous system discharge and were thus similar to the sequelae of bicuculline-induced seizures used as a model for epilepsy in sheep. 34 

A quantitative EEG approach allows precision in describing drug CNS effects by apportioning their time course into changes in the frequency spectrum and amplitude components. In this study, drug-induced EEG changes were measurable across all EEG frequency bands, but quantitative differences between drugs were revealed mainly in the low frequency (1–4 Hz) region. Doses greater than 24 μmol produced significant EEG and behavioral effects. Overall, these results concur with qualitative EEG data from much greater doses of congeneric local anesthetic agents given intravenously in monkeys. 35,36Apart from Na+channel blockade, local anesthetic drugs affect other neuronal receptor-mediated functions. 37At higher doses, they inhibit γ-aminobutyric acid receptor type A–mediated (GABAA-ergic) transmission 38–40and stimulate N -methyl-d-aspartate (NMDA) receptors, the latter apparently without alteration of cardiac toxicity. 41It is not yet known whether such actions are enantioselective. Although neural 42,43and cardiac 10,44Na+channel blockade is weakly enantioselective (dexbupivacaine-to-levobupivacaine potency ratio, 1.5), some other potentially relevant actions, such as on β2adrenoceptors 45and (rat) heart mitochondrial respiration, 46seem not to be demonstrably enantioselective.

It is clear that fatal arrhythmias did not result from direct CNS excitation or convulsions caused by CNS site-directed supraconvulsant doses of local anesthetic agents. At doses of 24 μmol, all three drugs caused mild overt CNS excitation, along with nonfatal cardiac arrhythmias, but without differences between drugs. At doses greater than 24 μmol, the three drugs caused marked convulsive behavior, but, again, fatal arrhythmias were not found. Nevertheless, because of the differences found previously between drugs in their potency for causing fatal arrhythmias with (supraconvulsant) intravenous doses, 1,4,5,7it is possible that bilateral carotid arterial infusion may not have delivered a sufficient amount of drug to the brain stem to show differential arrhythmogenic potency or cause fatal arrhythmias. Despite their practical difficulty, we therefore suggest that further refinements in experimental design are worthy of consideration, for example, by enriching CNS site-directed drug delivery to the brain stem via  the vertebral arterial supply or by preloading the heart with subtoxic amounts of drug before causing CNS excitatory effects. On the other hand, the possibility also remains that the small amounts of recirculated doses may have produced an antiarrhythmic effect. 47 

In summary, this study presents a further step in new techniques to probe the cardiac toxicity of clinically important local anesthetic agents. Although it found that bupivacaine was, overall, more potent toward direct CNS toxicity and indirect cardiac toxicity than levobupivacaine and ropivacaine, it did not find differences between the agents in nonfatal arrhythmogenicity nor did it find fatal arrhythmias resulting from CNS site-directed carotid arterial infusion.

The authors thank Mr. Ray Kearns, Animal House Manager, Ms. Janelle Young, Animal House Technician, and Ms. Sonia Gu, B.Sc., Research Assistant, (Centre for Anaesthesia and Pain Management Research, Royal North Shore Hospital, St. Leonards, Australia), for their skilled technical assistance.

Nancarrow C, Rutten AJ, Runciman WB, Mather LE, Carapetis RJ, McLean CF, Hipkins SF: Myocardial and cerebral drug concentrations and the mechanisms of death after fatal intravenous doses of lidocaine, bupivacaine and ropivacaine in the sheep. Anesth Analg 1989; 69: 276–83
Rutten AJ, Nancarrow C, Mather LE, Ilsley AH, Runciman WB, Upton RN: Hemodynamic and central nervous system effects of intravenous bolus doses of lidocaine, bupivacaine, and ropivacaine in sheep. Anesth Analg 1989; 69: 291–9
Santos AC, Arthur GR, Wlody D, De Armas P, Morishima HO, Finster M: Comparative systemic toxicity of ropivacaine and bupivacaine in nonpregnant and pregnant ewes. A nesthesiology 1995; 82: 734–40
Huang YF, Pryor ME, Mather LE, Veering BT: Cardiovascular and central nervous system effects of bupivacaine and levobupivacaine in sheep. Anesth Analg 1998; 86: 797–804
Santos AC, Karpel B, Noble G: The placental transfer and fetal effects of levobupivacaine, racemic bupivacaine, and ropivacaine. A nesthesiology 1999; 90: 1698–703
Santos A, DeArmas PI: Systemic toxicity of levobupivacaine, bupivacaine, and ropivacaine during continuous intravenous infusion to nonpregnant and pregnant ewes. A nesthesiology 2001; 95: 1256–64
Mather LE: Disposition of mepivacaine and bupivacaine enantiomers in the sheep. Br J Anaesth 1991; 67: 239–46
Åberg G: Toxicological and local anesthetic effects of optically active isomers of two local anesthetic compounds. Acta Pharmacol Toxicol 1972; 31: 273–86
Luduena F, Bogado E, Tullar B: Optical isomers of mepivacaine and bupivacaine. Arch Int Pharmacodyn Ther 1972; 200: 359–69
Vanhoutte F, Vereecke J, Verbeke N, Carmeliet E: Stereoselective effects of the enantiomers of bupivacaine on the electrophysiological properties of the guinea-pig papillary muscle. Br J Pharmacol 1991; 103: 1275–81
Mazoit J, Boico O, Samii K: Myocardial uptake of bupivacaine: II. Pharmacokinetics and pharmacodynamics of bupivacaine enantiomers in the isolated perfused rabbit heart. Anesth Analg 1993; 77: 477–82
Mazoit JX, Decaux A, Bouaziz H, Edouard A: Comparative ventricular electrophysiologic effect of racemic bupivacaine, levobupivacaine, and ropivacaine on the isolated rabbit heart. A nesthesiology 2000; 93: 784–92
Mather LE, Chang DH-T: Cardiotoxicity of local anaesthetics: Is there a safer choice? Drugs 2001; 61: 333–43
Heavner JE: Cardiac dysrhythmias induced by infusion of local anesthetics into the lateral cerebral ventricle of cats. Anesth Analg 1986; 65: 133–8
Thomas RD, Behbehani MM, Coyle DE, Denson DD: Cardiovascular toxicity of local anesthetics: An alternative hypothesis. Anesth Analg 1986; 65: 444–50
Denson DD, Behbehani MM, Gregg RV: Enantiomer-specific effects of an intravenously administered arrhythmogenic dose of bupivacaine on neurons of the nucleus tractus. Reg Anesth 1992; 17: 311–6
Chang DH-T, Ladd LA, Copeland S, Iglesias MI, Plummer JL, Mather LE: Direct cardiac effects of intracoronary bupivacaine, levobupivacaine and ropivacaine in the sheep. Br J Pharmacol 2001; 132: 649–58
Grant DA, Franzini C, Wild J, Walker AM: Continuous measurement of blood flow in the superior sagittal sinus of the lamb. Am J Physiol 1995; 38: R274–9
Baldwin BA, Bell FR: The anatomy of the cerebral circulation of the sheep and ox. The dynamic distribution of the blood supplied by the carotid and vertebral arteries to cranial regions. J Anat Lond 1963; 97: 203–15
May NDS: Arterial anastomoses in the head and neck of the sheep. J Anat Lond 1963; 2: 203–13
May NDS: Experimental studies of the collateral circulation in the head and neck of sheep (Ovis aries). J Anat Lond 1968; 103: 171–81
Ladd A, Mather LE: Central Effects Index—A semi-quantitative method for assessment of CNS toxicity of local anaesthetic agents in sheep. J Pharmacol Toxicol Meth 2000; 44: 467–76
Gu XQ, Fryirs B, Mather LE: High-performance liquid chromatographic separation and nanogram quantitation of bupivacaine enantiomers in blood. J Chromatogr B Biomed Sci Appl 1998; 719: 135–40
Matthews JNS, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ 1990; 300: 230–5
Brown H, Prescott R: Applied Mixed Models in Medicine. Chichester, John Wiley and Sons Ltd, 1999, pp 269–72
Frison L, Pocock SJ: Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. Stat Med 1992; 11: 1685–704
Chang D-HT, Ladd LA, Wilson KA, Gelgor L, Mather LE: Intravenous tolerability of large doses of levobupivacaine in sheep. Anesth Analg 2000; 91: 671–9
Bertrix L, Timour Q, Mazze RI, Freysz M, Samii K, Faucon G: Adverse interaction between bupivacaine and halothane on ventricular contractile force and intraventricular conduction in the dog. Anesth Analg 1991; 73: 434–40
Ohmura S, Ohta T, Yamamoto K, Kobayashi T: A comparison of the effects of propofol and sevoflurane on the systemic toxicity of intravenous bupivacaine in rats. Anesth Analg 1999; 88: 155–9
Runciman WB, Myburgh J, Upton RN, Mather LE: Effects of anaesthesia on drug disposition, Mechanisms of Action of Drugs in Anaesthetic Practice, 2nd edition. Edited by Feldman SA, Scurr CF, Paton W. London, Edward Arnold, 1993, pp 83–128
Aldrete JA, Romo-Salas F, Arora S, Wilson R, Rutherford R: Reverse arterial blood flow as a pathway for central nervous system toxic responses following injection of local anesthetics. Anesth Analg 1978; 57: 428–33
Perkins WJ, Lanier WL, Sharborough FW: Cerebral and hemodynamic effects of lidocaine accidentally injected into the carotid arteries of patients having carotid endarterectomy. A nesthesiology 1988; 69: 787–90
Shibata M, Shingu K, Murakawa M, Adachi T, Osawa M, Nakao S, Mori K: Tetraphasic actions of local anesthetics on central nervous system electrical activities in cats. Reg Anesth 1994; 19: 255–63
Johnston SC, Siedenberg R, Min JK, Jerome EH, Laxer KD: Central apnea and acute cardiac ischemia in a sheep model of epileptic sudden death. Ann Neurol 1997; 42: 588–94
Munson ES, Martucci RW, Wagman IH: Bupivacaine and lignocaine induced seizures in rhesus monkeys. Br J Anaesth 1972; 44: 1025–9
Malagodi MH, Munson ES, Embro WJ: Relation of etidocaine and bupivacaine toxicity to rate of infusion in rhesus monkeys. Br J Anaesth 1977; 49: 121–5
Gennery B, Mather LE, Strichartz G: Levobupivacaine: New preclinical and clinical data. Semin Anesth 2000; 19: 132–48
Ye JH, Ren J, Krnjeviè K, Liu PL, McArdle JJ: Cocaine and lidocaine have additive inhibitory effects on the GABAA current of acutely dissociated hippocampal pyramidal neurons. Brain Res 1999; 821: 26–32
Sugimoto M, Uchida I, Fukami S, Takenoshita M, Mashimo T, Toshiya I: The α and γ subunit-dependent effects of local anesthetics on recombinant GABAA receptors. Eur J Pharmacol 2000; 401: 329–37
Bernards CM, Artru AA: Effect of intracerebroventricular picrotoxin and muscimol on intravenous bupivacaine toxicity. Evidence supporting central nervous system involvement in bupivacaine cardiovascular toxicity. A nesthesiology 1993; 78: 902–10
Kasaba T, Shiraishi S, Taniguchi M, Takasaki M: Bupivacaine-induced convulsion is suppressed by MK-801. Reg Anesth Pain Med 1998; 23: 71–6
Nau C, Vogel W, Hemplemann G, Bräu ME: Stereoselectivity of bupivacaine in local anesthetic-sensitive ion channels of peripheral nerve. A nesthesiology 1999; 91: 786–95
Vladimirov M, Nau C, Mok WM, Strichartz G: Potency of bupivacaine stereoisomers tested in vitro and in vivo: Biochemical, electrophysiological, and neurobehavioral studies. A nesthesiology 2000; 93: 744–55
Nau C, Wang S-Y, Strichartz GR, Wang GK: Block of human heart hH1 sodium channels by the enantiomers of bupivacaine. A nesthesiology 2000; 93: 1022–33
Butterworth J, James RL, Grimes J: Structure-affinity relationships and stereospecificity of several homologous series of local anesthetics for the beta2-adrenergic receptor. Anesth Analg 1997; 85: 336–42
Sztark F, Nouette-Gaulain K, Malgat M, Dabadie P, Mazat JP: Absence of stereospecific effects of bupivacaine isomers on heart mitochondrial bioenergetics. A nesthesiology 2000; 93: 456–62
Picard S, Rouet R, Flais F, Ducouret P, Babatasi G, Khayat A, Potier JC, Bricard H, Gerard JL: Proarrhythmic and antiarrhythmic effects of bupivacaine in an in vitro model of myocardial ischemia and reperfusion. A nesthesiology 1998; 88: 1318–29